Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Major Program

Phase 0 I II Cancer Prevention Clinical Trials Program

Research Group

Breast and Gynecologic Cancer

Status

Completed

NCT ID

NCT03063619

This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Intervention

Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration

Condition

Mammographically Dense Breast

Investigators

Banu Arun, MD

See list of participating sites